Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 12/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931229 | 1.00 | GCK (0.42) | GCKPPARACCR5 | |
| SCHEMBL2647802 | 1.00 | GCK (0.42) | GCKPPARACCR5 | |
| SCHEMBL2656401 | 1.00 | GCK (0.42) | GCKPPARACCR5 | |
| SCHEMBL2647404 | 1.00 | GCK (0.42) | GCKPPARACCR5 | |
| SCHEMBL1931231 | 1.00 | GCK (0.42) | GCKPPARACCR5 | |
| SCHEMBL2659437 | 0.93 | GCK (0.47) | GCKPPARA | |
| SCHEMBL2659612 | 0.93 | GCK (0.47) | GCKPPARA | |
| SCHEMBL13609539 | 0.90 | GCK (0.40) | GCKPPARA | |
| SCHEMBL13609540 | 0.90 | GCK (0.40) | GCKPPARA | |
| SCHEMBL2676265 | 0.89 | PPARA (0.38) | GCKPPARACCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203207-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED T | 2007-08-30 | — | — | US | disclosed |
| US-7223868-B2 | Such as 2-(3-chloro-phenyl)-3-cyclopentyl-N-thiazol-2-yl-propionamide which increases insulin secretion in treatment of type II diabetes | HOFFMANN-LA ROCHE INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | BIZZARO FRED T | 2005-11-24 | — | — | US | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203207-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885PPARA 337/4885CCR5 4764/4885 |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885PPARA 337/4885CCR5 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.